Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does OMEPRAZOLE Cause Psychomotor hyperactivity? 48 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 48 reports of Psychomotor hyperactivity have been filed in association with OMEPRAZOLE (omeprazole sodium bicarbonate). This represents 0.1% of all adverse event reports for OMEPRAZOLE.

48
Reports of Psychomotor hyperactivity with OMEPRAZOLE
0.1%
of all OMEPRAZOLE reports
15
Deaths
33
Hospitalizations

How Dangerous Is Psychomotor hyperactivity From OMEPRAZOLE?

Of the 48 reports, 15 (31.3%) resulted in death, 33 (68.8%) required hospitalization.

Is Psychomotor hyperactivity Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for OMEPRAZOLE. However, 48 reports have been filed with the FAERS database.

What Other Side Effects Does OMEPRAZOLE Cause?

Chronic kidney disease (35,759) Acute kidney injury (19,260) Renal failure (14,721) End stage renal disease (10,356) Renal injury (9,482) Tubulointerstitial nephritis (4,809) Drug ineffective (4,355) Gastrooesophageal reflux disease (3,929) Pain (3,602) Nephrogenic anaemia (2,873)

What Other Drugs Cause Psychomotor hyperactivity?

METHYLPHENIDATE (617) QUETIAPINE (412) ARIPIPRAZOLE (389) OLANZAPINE (366) SERTRALINE (288) MONTELUKAST (282) RISPERIDONE (277) LEVETIRACETAM (247) VENLAFAXINE (214) LEVOTHYROXINE (211)

Which OMEPRAZOLE Alternatives Have Lower Psychomotor hyperactivity Risk?

OMEPRAZOLE vs OMEPRAZOLE\SODIUM BICARBONATE OMEPRAZOLE vs OMNIPAQUE OMEPRAZOLE vs OMNISCAN OMEPRAZOLE vs ONABOTULINUMTOXINA OMEPRAZOLE vs ONASEMNOGENE ABEPARVOVEC

Related Pages

OMEPRAZOLE Full Profile All Psychomotor hyperactivity Reports All Drugs Causing Psychomotor hyperactivity OMEPRAZOLE Demographics